GlassScriptPhysician profile
Jessica V Ribeiro
NPI 1447704200
$2,800.41
in general payments reported to CMS, 2019-2025
35 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $407 · 2023: $475 · 2024: $874 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $470.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $144.78 | 2021-2025 | Minimed 780g |
| Beta Bionics, INC. | $136.67 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $115.82 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $109.29 | 2021-2025 | |
| Corcept Therapeutics | $99.53 | 2023-2025 | Korlym |
| Abbott Laboratories | $98.82 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $81.04 | 2023-2024 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $79.08 | 2023-2025 | |
| Insulet Corporation | $76.52 | 2022-2024 | Omnipod |
| Radius Health, INC. | $74.24 | 2021-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $73.45 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.59 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $58.97 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $51.40 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $47.28 | 2023-2025 | |
| Mannkind Corporation | $43.73 | 2024 | |
| Dexcom, INC. | $38.57 | 2023-2025 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $35.73 | 2021 | |
| Intuity Medical INC | $35.36 | 2022 | |
| Xeris Pharmaceuticals, INC. | $33.98 | 2021-2024 | Recorlev |
| Recordati_rare_diseases_inc. | $33.87 | 2024-2025 | Isturisa |
| Amryt Pharma Holdings LTD | $23.78 | 2023 | Mycapssa |
| Sequel Med Tech, LLC | $22.51 | 2025 | Twiist |
| Kyowa Kirin, INC. | $20.83 | 2024 | Crysvita |
| Ibsa Pharma INC. | $18.67 | 2024 | Licart, Tirosint |
| Acella Pharmaceuticals, LLC | $18.45 | 2024 | NP Thyroid 60 |
| Alvogen INC | $16.69 | 2023 | Teriparatide |
| Amneal Pharmaceuticals LLC | $16.14 | 2021 | |
| Cequr Corporation | $15.95 | 2023 | Cequr Simplicity |
| Antares Pharma, INC. | $14.93 | 2025 | Xyosted |
| Amarin Pharma, INC. | $14.45 | 2021 | |
| Pfizer INC. | $13.67 | 2023 | |
| Clarus Therapeutics INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ribeiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.